Treatment with sitagliptin ameliorated body weight gain, lipid metabolic disorder, and steatosis as well as hepatic insulin resistance in leptin-deficient ob/ob mice by inhibiting inflammatory responses and activating autophagy through the AMPK/mTOR pathway [40]. The gene discussed is MTOR; the disease is steatosis.